Shares of Gilead Sciences were downgraded on Monday by not one but two firms, BMO Capital and Wells Fargo. The biotech giant was downgraded by the analysts who said it is fully valued amid market enthusiasm for its drug candidate to treat COVID-19, remdesivir. BMO Capital’s Matthew Luchini downgraded the stock to market perform from … Continue reading “Gilead Sciences Gets a Downgrade from BMO Capital and Wells Fargo”
